Get started
ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1

ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals Bonds

LLY chart


Full chart

Key facts today


Eli Lilly has filed a lawsuit against Strive Pharmacy and Empower Clinic Services for illegally producing and selling tirzepatide, the active ingredient in its weight-loss and diabetes medications.
Eli Lilly is boosting exports from Ireland to prepare for potential 25% tariffs on imported drugs and ingredients, fast-tracking shipments to avoid supply chain issues.
Eli Lilly's shares fell 1.6%, mirroring a 2.3% drop in the S&P 500 Pharmaceuticals index, amid major FDA layoffs initiated by the Trump administration.
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪819.04 T‬ ARS
Dividend yield (indicated)
0.39%
Price to earnings Ratio (TTM)
102.061
Basic EPS (TTM)
190.231 ARS
Net income (FY)
‪9.70 T‬ ARS
Revenue (FY)
‪41.24 T‬ ARS
Shares float
—
Beta (1Y)
0.26

About Eli Lilly and Company


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
David A. Ricks
Website
lilly.com
Headquarters
Indianapolis
Founded
1876
ISIN
ARDEUT111192
FIGI
BBG000HFTQS8
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

LLY news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

LLY highest yielding bonds


XS238628644
ELI LILLY 21/43
Yield to maturity
7.59%
Maturity date
Sep 14, 2043
US532457BY3
ELI LILLY 20/50
Yield to maturity
6.91%
Maturity date
May 15, 2050
US532457BZ0
ELI LILLY 20/60
Yield to maturity
6.82%
Maturity date
Sep 15, 2060
US532457AM0
ELI LILLY 2025
Yield to maturity
6.20%
Maturity date
Jun 1, 2025
US532457BT4
ELI LILLY 19/49
Yield to maturity
5.96%
Maturity date
Mar 15, 2049
US532457BU1
ELI LILLY 19/59
Yield to maturity
5.94%
Maturity date
Mar 15, 2059
LLYC
ELI LILLY 15/25
Yield to maturity
5.88%
Maturity date
Jun 1, 2025
US532457BS6
ELI LILLY 19/39
Yield to maturity
5.76%
Maturity date
Mar 15, 2039
LLY4217068
Eli Lilly and Company 3.7% 01-MAR-2045
Yield to maturity
5.74%
Maturity date
Mar 1, 2045
LLY4492882
Eli Lilly and Company 3.95% 15-MAY-2047
Yield to maturity
5.71%
Maturity date
May 15, 2047
LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044
Yield to maturity
5.67%
Maturity date
Jun 15, 2044

See all LLY bonds 

Sparks


Curated watchlists where LLY is featured.

See all sparks 


Check out other big names from the same industry as LLY.